Search Bar & Filters
Found 17 Actively Recruiting clinical trials
Actively Recruiting
This research aims to evaluate the effects of TAK-330 compared to standard four-factor prothrombin complex concentrate 4F-PCC in adults treated with Factor Xa inhibitors who need urgent surgery or invasive procedures. The study focuses on reversing anticoagulation caused by Factor Xa inhibitors and is a Phase 3, randomized, triple-blind trial sponsored by Takeda. Participants will be randomly assigned to receive either TAK-330 or the standard 4F-PCC. TAK-330 is given as a single intravenous infusion dose of 25 IUkg before surgery, with an optional additional 25 IUkg dose during surgery if needed, not exceeding a total of 50 IUkg or 5,000 IU. The standard 4F-PCC dose and infusion speed follow local protocols, with an additional dose allowed during surgery under the same maximum limits. These treatments are administered during hospitalization prior to surgery. During the study, participants will be hospitalized for the surgery and treatment administration, with assessments of hemostasis effectiveness at surgery end and 24 hours after treatment. Researchers will monitor blood product use, adverse events including thrombotic events, and participant survival up to 30 days after surgery. Follow-up will also include contact via telehealth or phone 30 days post-surgery to evaluate safety and outcomes. Total participation duration covers the hospital stay and the 30-day post-surgery monitoring period.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of belumosudil compared with a placebo in adults with chronic lung allograft dysfunction CLAD after bilateral lung transplantation. This Phase 3, double-blind, randomized, placebo-controlled study involves participants at least one year post-transplant who have progressive CLAD despite azithromycin treatment. The study aims to understand how belumosudil affects lung function, specifically forced expiratory volume in 1 second FEV1. Participants will be randomly assigned to receive either 200 mg of oral belumosudil once daily or a placebo, both alongside azithromycin and standard immunosuppressive care. The treatment period lasts up to 26 weeks for those not entering the open-label extension OLE, and up to 52 weeks for those who do. Participants entering the long-term OLE will continue treatment and study visits every 12 weeks as per protocol. During the study, participants will attend up to 10 visits or up to 16 visits if entering the OLE. Researchers will measure lung function changes, walk distance, quality of life through questionnaires, and record any adverse events. The primary outcome is the percent change in FEV1 from baseline to Week 26. Safety and other lung function measures will also be closely monitored throughout the study and extension periods.
Actively Recruiting
Researchers are evaluating the safety and performance of Abbotts commercially available Structural Heart SH devices in real-world hospital settings. This observational registry collects data to meet regulatory requirements, such as the European Union Medical Device Regulations 2017745, by actively monitoring these devices after market approval. The study includes patients undergoing standard care procedures involving Abbott SH devices, with a focus on confirming device safety and performance across multiple device types. Participants receive one or more Abbott SH devices during routine hospital procedures, including Amplatzer Occlusion Devices for septal defects and Epic Surgical Tissue Heart Valve devices for heart valve replacement. The registry enrolls patients either before the procedure or shortly after, depending on the device type, with follow-up visits aligned with standard care schedules. Follow-up may include discharge or 7-day post-procedure visits, short-term 1-3 months, mid-term 6 months, and long-term up to 12 months or even 10 years assessments depending on the device used. A specific surgical valve sub-study collects additional data for certain valve sizes to support regulatory approval in the US. Participants are monitored through their routine care visits, which may occur in person, by phone, or virtually. Data collected include safety and effectiveness outcomes at various time points post-procedure. The registry plans to enroll approximately 500 subjects annually across about 25 global sites, with follow-up duration varying by device type to cover short- and long-term safety and performance. The total study completion is expected by November 2039, allowing extended monitoring of patient outcomes.
Actively Recruiting
Researchers are gathering real-world data on the outcomes of patients with perimembranous ventricular septal defects PmVSD, a heart condition, who have undergone transcatheter closure using various device occluders. This international, multicenter, non-interventional, observational study aims to evaluate how well these devices work and their safety when used in both children and adults. The study focuses on patients treated with devices either specifically designed for PmVSD closure or used off-label. Participants in this study have had their PmVSD closed using commercially available occluder devices through a transcatheter procedure. The devices are placed without open-heart surgery to close the defect. The study observes patients who have already undergone this procedure and collects follow-up data according to each hospitals usual practice. The study does not intervene but monitors how these devices perform over time. Participants will be followed for up to 60 months after their procedure to assess clinical success, technical success, closure success, and any device-related complications. Researchers will also evaluate functional outcomes and quality of life for up to 48 months post-procedure. Data collection includes clinical events from the implant attempt through the follow-up period, and safety is monitored by tracking adverse events. The total duration of participation depends on the timing of the procedure and follow-up visits according to local protocols.
Actively Recruiting
Congenital heart defects CHD are a major cause of birth defects affecting millions worldwide, including about 41,000 newborns annually in Europe. CHD is linked with high rates of illness and death throughout life, and over half of infants with critical CHD develop neurodevelopmental disorders NDDs. These NDDs involve early disruptions in brain development affecting cognitive, emotional, and behavioral functions, often leading to challenges in language, learning, motor skills, and social interactions. The CATAMARAN neonatal cohort project seeks to detect developmental delays as early as six months in infants with CHD and to identify factors that contribute to these delays. The study includes 150 fetuses diagnosed prenatally with critical CHD requiring cardiac surgery within the first three months of life, along with their two parents. Researchers will perform neurodevelopmental assessments using the Bayley-IV test and collect various biological samples at delivery and during hospitalization for surgery. These samples include maternal and infant blood, placenta tissue, and stool for genetic, metabolomic, microbiome, and other analyses. Additional data on pregnancy, obstetric events, fetal ultrasounds, echocardiography, and parental stress levels will also be gathered. Participants will be monitored at six months of age to evaluate the prevalence and specifics of developmental delays. The study will assess how genetic factors, placental anomalies, maternal behaviors, and surgical details relate to these delays. Parents will complete questionnaires about diet and post-traumatic stress. Researchers will collect cardiovascular and developmental follow-up data, postoperative brain MRI scans, and track neonatal microbiota to better understand the origins and impacts of neurodevelopmental disorders in infants with CHD.
Actively Recruiting
This research aims to collect real-world information about the treatment of lesions in the peripheral vasculature, focusing on patients who may not have been included in previous Peripheral Vascular Disease PVD studies. It evaluates the use of commercially available drug-eluting devices made by Boston Scientific Corporation to better understand their application and health economic impact globally. Participants in this registry receive treatment with Boston Scientific drug-eluting devices such as the Ranger14 Paclitaxel-Coated PTA Balloon Catheter and the ELUVIA14 Drug-Eluting Vascular Stent System. The study is observational and includes patients from multiple countries, with follow-up lasting up to 2 years in most countries and up to 5 years in China. Some participants at select sites will also complete additional assessments like quality of life questionnaires, six-minute walk tests, and healthcare utilization data collection. Throughout the study, participants undergo assessments based on standard care procedures. Researchers will monitor major adverse events and lesion patency at 12 months. Data collected includes health economics and patient outcomes to support the safe use of these devices. The total study duration extends up to 5 years depending on location, with scheduled follow-ups to gather ongoing information about treatment effects and patient health.
Actively Recruiting
Researchers are evaluating the impact of different fluid removal strategies in intensive care unit ICU patients with acute kidney injury AKI who are receiving renal replacement therapy RRT. The goal is to see if a higher rate of fluid removal net ultrafiltration guided by tissue perfusion parameters can improve overall health outcomes compared to a lower, stabilizing fluid removal rate. This study aims to address the risks of fluid overload, which is linked to worse health outcomes, and balance it with the risk of reduced blood volume that can cause tissue damage. Participants are randomly assigned to one of two groups. The experimental group receives a higher ultrafiltration rate of 2 mlkgh to reduce fluid overload until the patients baseline body weight is reached, with adjustments based on tolerance and tissue perfusion. The control group receives a lower ultrafiltration rate between 0 and 1 mlkgh aimed at stabilizing fluid balance without targeting weight loss. In case of intolerance or failure to reach targets, ultrafiltration rates are adjusted accordingly. During the study, patients are monitored closely for organ function, fluid balance, and tissue perfusion. Researchers will assess outcomes such as days free from organ support, kidney recovery, time on ventilator and vasopressors, ICU stay length, and occurrence of complications like arrhythmias or intestinal ischemia. The primary outcome is the number of organ replacement-free days by day 30. The study involves randomization, single masking, and will continue until January 2028.
Actively Recruiting
Researchers are investigating the relationship between cannabis use and lung cancer, focusing on patients aged 18 to 59 years treated for primary lung cancer. Cannabis is widely consumed and has recognized neuro-psychic effects, but its impact on lung cancer development remains uncertain. Previous studies suggest cannabis smoke contains more carcinogens than tobacco smoke, and clinical observations have raised concerns about cannabis possibly contributing to more aggressive lung cancers in young patients who are heavy users. The study categorizes participants into three groups cannabis smokers who also use tobacco, tobacco-only smokers, and non-smokers. Participants will provide blood and hair samples to support the research. This study is non-randomized and does not involve blinding. The primary measure is the percentage of patients who are active cannabis smokers, defined as smoking at least 10 joints per month for at least one year. Participants will be monitored for cannabis use status, and researchers will collect biological samples to analyze potential differences in lung cancer profiles across groups. The study aims to understand the prevalence of cannabis smoking among lung cancer patients and its possible influence on disease characteristics. This involvement includes consenting to sample collection and data recording during their treatment period, with the research spanning multiple hospitals.
Actively Recruiting
This research aims to assess the safety and performance of Cooks various custom-made stent-graft devices used for endovascular treatment of complex abdominal aortic aneurysms, thoracoabdominal aortic aneurysms, aortic arch aneurysms, and chronic aortic dissections. The study collects real-world data on the use of these devices to support their ongoing market availability and post-market surveillance as well as further technological development by Cook. Participants will receive treatment using Cooks custom-made endovascular grafts designed for complex aortic diseases. The study is observational and does not involve assigning participants to specific treatment groups but rather monitors patients receiving these devices in usual care settings. During the study, researchers will track treatment success rates at 12 months and safety outcomes within 30 days after treatment. Participants will undergo clinical follow-up visits to monitor outcomes. The study results will contribute to understanding device performance and safety in real-world use. The study will continue until December 2030.
Actively Recruiting
Researchers are collecting real-world data on the Ion endoluminal system, a device used for lung nodule biopsies and localization in patients with pulmonary nodules or lung cancer. This observational study aims to evaluate the procedural details and both short- and long-term clinical outcomes following use of this CE-marked system. The study will enroll about 1,200 patients undergoing biopsy or localization procedures per approved indications. Participants will undergo lung nodule biopsy andor localization using the Ion endoluminal system according to routine care at the study sites. This is a single-arm, prospective study without experimental treatment assignment, focusing on real-world use of the device. The study will continue enrolling until the target number of patients is reached. During the study, participants will be monitored from the procedure through up to 24 months afterward to assess diagnostic yield. Additional safety outcomes such as pneumothorax and bleeding will be tracked through 30 days post-procedure. Participants will receive standard follow-up and assessments as part of their clinical care, with data collected to evaluate device performance and patient outcomes over time.
1-10 of 17
1